En español
NIDA

Focused Opioid Use Disorder Medications Development Research Project

Goal: Conduct a series of high-impact studies that will ideally lead to about 15 Investigational New Drugs (INDs), which would then produce around five New Drug Applications (NDAs) submitted to the Food and Drug Administration (FDA).

This project will focus on developing new addiction treatments and overdose-reversal tools. Three medications are currently FDA-approved to treat opioid addiction, and naloxone is available in both injectable and intranasal formulations to reverse overdose. But a wider range of options is needed in both areas. These may involve new formulations of existing drugs including longer-acting depot formulations of opioid agonists as well as stronger, longer-lasting naloxone formulations to more effectively reverse overdose from powerful synthetic opioids such as fentanyl. Research will also focus on compounds that target different receptor systems or immunotherapies to treat symptoms of withdrawal and craving in addition to the progression of opioid use disorders.

NIDA Contact: Dr. Kurt Rasmussen

Grants Awarded to Date